Merck Sues Over Medicare Drug-Price Negotiation Law - The New York Times
▻https://www.nytimes.com/2023/06/06/business/merck-medicare-drug-prices.html
Only some drugs will be subject to negotiation with Medicare and only after they have been on the market without competition for years. But Merck, which generated $14.5 billion in profit last year, claimed in a statement on Tuesday that the law would stifle the ability of it and its peers to make risky investments in new cures.